Literature DB >> 16716822

Management of malignant pleural mesothelioma.

Sophie D West1, Y C Gary Lee.   

Abstract

Malignant mesothelioma is increasing in incidence globally and has no known cure. Its unique clinical feature of local infiltration along tissue planes makes it a difficult neoplasm to manage. There have been few randomized controlled trials regarding treatment options, although these have increased in recent years, and results are eagerly awaited. This article summarizes important advances in the management of mesothelioma, especially diagnostic and therapeutic aspects.

Entities:  

Mesh:

Year:  2006        PMID: 16716822     DOI: 10.1016/j.ccm.2006.01.004

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  16 in total

1.  Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?

Authors:  Y C Gary Lee
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

2.  FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.

Authors:  E Incerti; S Broggi; A Fodor; M Cuzzocrea; A M Samanes Gajate; P Mapelli; C Fiorino; I Dell'Oca; M Pasetti; M Cattaneo; R Calandrino; L Gianolli; N Di Muzio; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

3.  Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.

Authors:  Huseyin Yildirim; Muzaffer Metintas; Güntülü Ak; Sinan Erginel; Fusun Alatas; Emel Kurt; Selma Metintas; Irfan Ucgun
Journal:  Lung       Date:  2007-10-19       Impact factor: 2.584

4.  In vitro and in vivo characterization of highly purified human mesothelioma derived cells.

Authors:  Alice Melotti; Antonio Daga; Daniela Marubbi; Annalisa Zunino; Luciano Mutti; Giorgio Corte
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

Review 5.  Malignant pleural mesothelioma: current and future perspectives.

Authors:  Konstantinos Porpodis; Paul Zarogoulidis; Efimia Boutsikou; Antonis Papaioannou; Nikolaos Machairiotis; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Bojan Zaric; Branislav Perin; Haidong Huang; Ioanna Kougioumtzi; Dionysios Spyratos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 6.  Management options for malignant pleural mesothelioma: clinical and cost considerations.

Authors:  Ranjit K Goudar
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Mesothelioma v/s adenocarcinoma of lung do serum markers help?

Authors:  Neeraj Gupta
Journal:  Lung India       Date:  2008-10

8.  Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.

Authors:  Viviana Volta; Elia Ranzato; Simona Martinotti; Simone Gallo; Maria Veronica Russo; Luciano Mutti; Stefano Biffo; Bruno Burlando
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

9.  Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.

Authors:  Jun Huang; Sho Tabata; Soji Kakiuchi; Trung The Van; Hisatsugu Goto; Masaki Hanibuchi; Yasuhiko Nishioka
Journal:  Oncotarget       Date:  2013-08

10.  Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Authors:  Jenette Creaney; Sophie Sneddon; Ian M Dick; Hanne Dare; Neil Boudville; Arthur William Musk; Steven J Skates; Bruce W S Robinson
Journal:  Dis Markers       Date:  2013-08-06       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.